Data / Drug companies / Bionpharma Inc.
Bionpharma Inc.: 187 products in the FDA NDC directory, labeler code 69452
Bionpharma Inc. (labeler code 69452) lists 187 products in the FDA National Drug Code Directory, covering 90 finished drugs by generic name. By type: 124 prescription drugs, 59 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 30, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 69452
- Products in commercial distribution
- 187
- Packages
- 274
- Finished drugs by generic name
- 90
- Prescription products
- 124
- Over the counter products
- 59
- Controlled substance products
- Schedule IV 8
- Flagged as original packager
- 172 of 172 products that carry the flag
- Started marketing in the last 12 months
- 24
- Earliest marketing start
- June 15, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 146 | 78.1% |
| Over the counter monograph drugs | 30 | 16% |
| New drug applications (NDA) | 7 | 3.7% |
| Drugs for further processing | 4 | 2.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 124 | 66.3% |
| Over the counter drugs | 59 | 31.6% |
| Drugs for further processing | 4 | 2.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 41 | 21.9% |
| Capsule, liquid filled | 35 | 18.7% |
| Tablet | 29 | 15.5% |
| Capsule | 27 | 14.4% |
| Solution | 10 | 5.3% |
| Liquid | 9 | 4.8% |
| Tablet, orally disintegrating | 8 | 4.3% |
| Tablet, delayed release | 6 | 3.2% |
| Suspension | 5 | 2.7% |
| Tablet, for suspension | 3 | 1.6% |
| Cream | 2 | 1.1% |
| Capsule, extended release | 2 | 1.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Colesevelam hydrochloride | 69452-582 | Tablet, film coated | Generic drugs (ANDA) | September 30, 2026 |
| Gas relief | 69452-581 | Capsule, liquid filled | Over the counter monograph drugs | September 30, 2026 |
| Pinworm medicine | 69452-512 | Tablet, chewable | Over the counter monograph drugs | September 30, 2026 |
| Docosanol | 69452-550 | Cream | Generic drugs (ANDA) | September 8, 2026 |
| Dextromethorphan HBr | 69452-573 | Capsule, liquid filled | Over the counter monograph drugs | August 31, 2026 |
| Olanzapine | 69452-564 | Tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2026 |
| Olanzapine | 69452-563 | Tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2026 |
| Olanzapine | 69452-562 | Tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2026 |
| Olanzapine | 69452-561 | Tablet, orally disintegrating | Generic drugs (ANDA) | July 1, 2026 |
| Cetirizine HCl | 69452-479 | Capsule | New drug applications (NDA) | May 25, 2026 |
| Pain relief pm | 69452-507 | Capsule, liquid filled | Generic drugs (ANDA) | May 20, 2026 |
| Glycopyrrolate | 69452-406 | Solution | Generic drugs (ANDA) | May 11, 2026 |
| Ultra strength gas relief | 69452-543 | Capsule, liquid filled | Over the counter monograph drugs | April 1, 2026 |
| Gas relief | 69452-542 | Capsule, liquid filled | Over the counter monograph drugs | April 1, 2026 |
| Loperamide Hydrochloride | 69452-405 | Solution | Generic drugs (ANDA) | March 2, 2026 |
| Loperamide hydrochloride oral | 69452-405 | Solution | Drugs for further processing | February 27, 2026 |
| Stimulant laxative | 69452-541 | Tablet, delayed release | Over the counter monograph drugs | February 23, 2026 |
| Colesevelam hydrochloride | 69452-493 | Tablet | Generic drugs (ANDA) | February 12, 2026 |
| Acetaminophen and Ibuprofen | 69452-469 | Tablet, film coated | Generic drugs (ANDA) | January 13, 2026 |
| Loperamide hydrochloride and Simethicone | 69452-531 | Tablet | Generic drugs (ANDA) | January 7, 2026 |
| Etravirine | 69452-255 | Tablet | Generic drugs (ANDA) | January 1, 2026 |
| Etravirine | 69452-254 | Tablet | Generic drugs (ANDA) | January 1, 2026 |
| Cetirizine Hydrochloride | 69452-426 | Solution | Generic drugs (ANDA) | December 1, 2025 |
| Acamprosate Calcium | 69452-353 | Tablet, delayed release | Generic drugs (ANDA) | December 1, 2025 |
| Ticagrelor | 69452-509 | Tablet | Generic drugs (ANDA) | October 28, 2025 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.